Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD 1.835
-0.060 (-3.17%)
May 18, 2026, 4:10 PM AEST
Australian Clinical Labs Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Income | 26.31 | 32.43 | 23.93 | 35.9 | 178.24 | 60.37 |
Depreciation & Amortization | 134.93 | 136.04 | 128.43 | 122.76 | 106.1 | 88.05 |
Loss (Gain) From Sale of Assets | 0.04 | 0.04 | 1.04 | -0.14 | 0.67 | -0.03 |
Stock-Based Compensation | 3.44 | 3.44 | 3.06 | 1.88 | 1.46 | 2.17 |
Other Operating Activities | -9.61 | 1.38 | 2.64 | -10.48 | 8.14 | -9.71 |
Change in Accounts Receivable | 8.32 | 8.32 | -7.72 | 17.4 | -28.12 | 2.75 |
Change in Inventory | 1.21 | 1.21 | -1.73 | 5 | -3.9 | -2.26 |
Change in Accounts Payable | -0.03 | -0.03 | 11.65 | -17.73 | 16.49 | 5.18 |
Change in Other Net Operating Assets | -0.04 | -0.04 | -1.71 | -10.91 | 5.01 | 7.34 |
Operating Cash Flow | 164.57 | 182.8 | 159.59 | 143.68 | 284.09 | 153.86 |
Operating Cash Flow Growth | -1.54% | 14.54% | 11.07% | -49.42% | 84.64% | 51.24% |
Capital Expenditures | -7.88 | -8.41 | -6.51 | -6.93 | -21.25 | -9.51 |
Sale of Property, Plant & Equipment | 0.14 | 0.1 | 0.33 | 0.24 | 0.27 | 0.11 |
Cash Acquisitions | -0.58 | -0.58 | -1.07 | -5.48 | -51.06 | 2.25 |
Investment in Securities | - | - | - | - | - | 1.07 |
Investing Cash Flow | -8.32 | -8.9 | -7.25 | -12.18 | -72.04 | -6.08 |
Long-Term Debt Issued | - | 31 | 14 | 100.5 | - | 321.6 |
Total Debt Issued | 40 | 31 | 14 | 100.5 | - | 321.6 |
Long-Term Debt Repaid | - | -165.68 | -138.06 | -140.61 | -191.69 | -357.22 |
Total Debt Repaid | -145.25 | -165.68 | -138.06 | -140.61 | -191.69 | -357.22 |
Net Debt Issued (Repaid) | -105.25 | -134.68 | -124.06 | -40.11 | -191.69 | -35.62 |
Issuance of Common Stock | - | - | - | - | - | 146.25 |
Repurchase of Common Stock | -24.68 | -19.12 | -1.74 | -0.89 | -4.94 | - |
Common Dividends Paid | -24.42 | -24.95 | -19.95 | -96.88 | -24.22 | -42 |
Other Financing Activities | -0.31 | - | -0.39 | - | -0.06 | -216 |
Financing Cash Flow | -154.65 | -178.74 | -146.14 | -137.88 | -220.91 | -147.37 |
Foreign Exchange Rate Adjustments | 0.02 | 0.14 | -0.03 | -0.04 | 0.01 | -0.03 |
Net Cash Flow | 1.62 | -4.69 | 6.18 | -6.42 | -8.86 | 0.38 |
Free Cash Flow | 156.7 | 174.39 | 153.09 | 136.75 | 262.84 | 144.36 |
Free Cash Flow Growth | -2.35% | 13.92% | 11.95% | -47.97% | 82.07% | 56.31% |
Free Cash Flow Margin | 21.25% | 23.53% | 21.98% | 19.62% | 26.40% | 22.32% |
Free Cash Flow Per Share | 0.84 | 0.92 | 0.77 | 0.68 | 1.30 | 0.95 |
Cash Interest Paid | 17.52 | 18.46 | 16.67 | 13.85 | 11.39 | 39.39 |
Cash Income Tax Paid | 21.61 | 14.43 | 10.16 | 17.91 | 68.87 | 18.56 |
Levered Free Cash Flow | 168.14 | 178.08 | 161.24 | 126.48 | 250.39 | 170.88 |
Unlevered Free Cash Flow | 177.13 | 187.2 | 168.85 | 134.9 | 257.74 | 180.34 |
Change in Working Capital | 9.46 | 9.46 | 0.49 | -6.24 | -10.52 | 13 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.